Adamis Pharmaceuticals Corp ADMP has initiated a process to explore a range of strategic and financing alternatives.
The move follows the recently announced halting of the company’s Phase 2/3 trial examining the effects of Tempol in high-risk subjects with early COVID-19 infection.
In March this year, Adamis voluntarily recalled certain lots of Symjepi (epinephrine) Injection 0.15 mg and 0.3 mg pre-filled single-dose syringes to the consumer level due to the potential clogging of the needle preventing the dispensing of epinephrine.
Potential alternatives that may be explored or evaluated include a partnership or sale of one or both of the company’s commercial products, Symjepi and Zimhi, a merger, sale, or reverse merger of the company, and/or seeking additional financing.
The company has engaged the investment bank Raymond James & Associates, Inc. as a strategic advisor to assist the company in evaluating options.
If the company cannot complete a transaction, it may be required to seek bankruptcy protection or other alternatives for restructuring and resolving its liabilities.
ADMP also intends to pursue expense reduction alternatives, including job cuts.
Price Action: ADMP shares closed 5.75% higher at $0.17 during after-hours trading on Monday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
